358 related articles for article (PubMed ID: 26615130)
1. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK; Park JI
Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
3. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
4. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
5. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Caunt CJ; Sale MJ; Smith PD; Cook SJ
Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
[TBL] [Abstract][Full Text] [Related]
6. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
7. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
9. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
10. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
11. The clinical development of MEK inhibitors.
Zhao Y; Adjei AA
Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.
Sale MJ; Cook SJ
Biochem Soc Trans; 2014 Aug; 42(4):776-83. PubMed ID: 25109957
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
14. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
15. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
16. MEK1/2 dual-specificity protein kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953
[TBL] [Abstract][Full Text] [Related]
17. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.
Frémin C; Meloche S
J Hematol Oncol; 2010 Feb; 3():8. PubMed ID: 20149254
[TBL] [Abstract][Full Text] [Related]
18. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
Yari H; Ganjalikhany MR; Sadegh H
Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563
[TBL] [Abstract][Full Text] [Related]
19. The biology and clinical development of MEK inhibitors for cancer.
Luke JJ; Ott PA; Shapiro GI
Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]